Affiliation:
1. Columbia University Irving Medical Center
Abstract
Abstract
Biomarkers play a crucial role in advancing precision medicine by enabling more targeted and individualized approaches to diagnosis and treatment. Various biofluids, including serum, plasma, cerebrospinal fluid (CSF), saliva, tears, pancreatic cyst fluids, and urine, have been identified as rich sources of potential for the early detection of disease biomarkers in conditions such as cancer, cardiovascular diseases, and neurodegenerative disorders. The analysis of plasma and serum in proteomics research encounters challenges due to their high complexity and the wide dynamic range of protein abundance. These factors impede the sensitivity, coverage, and precision of protein detection when employing mass spectrometry, a widely utilized technology in discovery proteomics. Conventional approaches such as neat plasma workflow are inefficient in accurately quantifying low-abundant proteins, including those associated with tissue leakage, immune response molecules, interleukins, cytokines, and interferons. Moreover, the manual nature of the workflow poses a significant hurdle in conducting large cohort studies. In this study, our focus is on comparing workflows for plasma proteomic profiling to establish a methodology that is not only sensitive and reproducible but also applicable for large cohort studies in biomarker discovery. Our investigation revealed that the SeerProteographXT workflow outperforms other workflows in terms of plasma proteome depth, quantitative accuracy, and reproducibility while offering complete automation of sample preparation. Notably, SeerProteographXT demonstrates versatility by applying it to various types of biofluids. Additionally, the proteins quantified widely cover secretory proteins in peripheral blood, and the pathway analysis enriched with relevant components such as interleukins, tissue necrosis factors, chemokines, and B and T cell receptors provides valuable insights. These proteins, often challenging to quantify in complex biological samples, hold potential as early detection markers for various diseases, thereby contributing to the improvement of patient care quality.
Publisher
Research Square Platform LLC
Reference20 articles.
1. What are Biomarkers?;Strimbu K;Curr Opin HIV AIDS,2010
2. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework;Biomarkers Definition Working Group;Clin Pharmacol Ther,2001
3. Veenstra TD. The Search for Biomarkers in Biofluids. Proteomic Applications in Cancer Detection and Discovery, First Edition. (John Wiley &Sons, Inc). 2013; 01 July.
4. Multiple Cause of Death 2018–2021 on CDC WONDER Database;National Center for Health Statistics;Accessed Febr,2023
5. Heart Disease and Stroke Statistics—2023 Update: A Report From the American Heart Association;Tsao CW;Circulation